Replies to post #150786 on Biotech Values

[DewDiligence]

The bad blood had to do with the successor CD20 product.

[masterlongevity]

there have been constant legal and almost leagal battles on Rituxan, ocrelizumab and GA101.

BIIB generally loses each time